{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T20:03:24Z","timestamp":1786133004083,"version":"build-2736575974"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JASN"],"published-print":{"date-parts":[[2016,5]]},"abstract":"<jats:p>Among patients with ESRD, cancer risk is affected by kidney dysfunction and by immunosuppression after transplant. Assessing patterns across periods of dialysis and kidney transplantation may inform cancer etiology. We evaluated 202,195 kidney transplant candidates and recipients from a linkage between the Scientific Registry of Transplant Recipients and cancer registries, and compared incidence in kidney function intervals (time with a transplant) with incidence in nonfunction intervals (waitlist or time after transplant failure), adjusting for demographic factors. Incidence of infection-related and immune-related cancer was higher during kidney function intervals than during nonfunction intervals. Incidence was most elevated for Kaposi sarcoma (hazard ratio [HR], 9.1; 95% confidence interval (95% CI), 4.7 to 18), non-Hodgkin\u2019s lymphoma (HR, 3.2; 95% CI, 2.8 to 3.7), Hodgkin\u2019s lymphoma (HR, 3.0; 95% CI, 1.7 to 5.3), lip cancer (HR, 3.4; 95% CI, 2.0 to 6.0), and nonepithelial skin cancers (HR, 3.8; 95% CI, 2.5 to 5.8). Conversely, ESRD-related cancer incidence was lower during kidney function intervals (kidney cancer: HR, 0.8; 95% CI, 0.7 to 0.8 and thyroid cancer: HR, 0.7; 95% CI, 0.6 to 0.8). With each successive interval, incidence changed in alternating directions for non-Hodgkin\u2019s lymphoma, melanoma, and lung, pancreatic, and nonepithelial skin cancers (higher during function intervals), and kidney and thyroid cancers (higher during nonfunction intervals). For many cancers, incidence remained higher than in the general population across all intervals. These data indicate strong short-term effects of kidney dysfunction and immunosuppression on cancer incidence in patients with ESRD, suggesting a need for persistent cancer screening and prevention.<\/jats:p>","DOI":"10.1681\/asn.2015040373","type":"journal-article","created":{"date-parts":[[2015,11,12]],"date-time":"2015-11-12T21:20:03Z","timestamp":1447363203000},"page":"1495-1504","source":"Crossref","is-referenced-by-count":107,"title":["Variation in Cancer Incidence among Patients with ESRD during Kidney Function and Nonfunction Intervals"],"prefix":"10.1681","volume":"27","author":[{"given":"Elizabeth L.","family":"Yanik","sequence":"first","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina A.","family":"Clarke","sequence":"additional","affiliation":[{"name":"Cancer Prevention Institute of California, Fremont, California;"},{"name":"Department of Health Research and Policy, Stanford University School of Medicine and Stanford Cancer Institute, Palo Alto, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon J.","family":"Snyder","sequence":"additional","affiliation":[{"name":"Scientific Registry of Transplant Recipients, Minneapolis Medical Research Foundation, Minneapolis, Minnesota; and"},{"name":"Division of Epidemiology and Community Health, University of Minnesota, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth M.","family":"Pfeiffer","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A.","family":"Engels","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2015,11,12]]},"reference":[{"key":"B1-20230819","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1001\/jama.2011.1592","article-title":"Spectrum of cancer risk among US solid organ transplant recipients.","volume":"306","author":"Engels","year":"2011","journal-title":"JAMA"},{"key":"B2-20230819","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0140-6736(99)06154-1","article-title":"Cancer in patients on dialysis for end-stage renal disease: an international collaborative study.","volume":"354","author":"Maisonneuve","year":"1999","journal-title":"Lancet"},{"key":"B3-20230819","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1001\/jama.296.23.2823","article-title":"Cancer incidence before and after kidney transplantation.","volume":"296","author":"Vajdic","year":"2006","journal-title":"JAMA"},{"key":"B4-20230819","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1093\/ndt\/gfn183","article-title":"Cancer in patients on dialysis and after renal transplantation.","volume":"23","author":"Fischereder","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"B5-20230819","doi-asserted-by":"crossref","first-page":"c570","DOI":"10.1136\/bmj.c570","article-title":"Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study.","volume":"340","author":"van Leeuwen","year":"2010","journal-title":"BMJ"},{"key":"B6-20230819","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1158\/1055-9965.EPI-08-0919","article-title":"Immunosuppression and other risk factors for lip cancer after kidney transplantation.","volume":"18","author":"van Leeuwen","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B7-20230819","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1158\/1055-9965.EPI-09-0278","article-title":"Cutaneous melanoma is related to immune suppression in kidney transplant recipients.","volume":"18","author":"Vajdic","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B8-20230819","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/ajh.23726","article-title":"Risk of diffuse large B-cell lymphoma after solid organ transplantation in the United States.","volume":"89","author":"Gibson","year":"2014","journal-title":"Am J Hematol"},{"key":"B9-20230819","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1182\/blood-2009-02-202507","article-title":"Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation.","volume":"114","author":"van Leeuwen","year":"2009","journal-title":"Blood"},{"key":"B10-20230819","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/ijc.22281","article-title":"Risk factors for human Herpesvirus 8 infection and AIDS-associated Kaposi\u2019s sarcoma among men who have sex with men in a European multicentre study.","volume":"120","author":"Martr\u00f3","year":"2007","journal-title":"Int J Cancer"},{"key":"B11-20230819","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/cid\/cit369","article-title":"Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy.","volume":"57","author":"Yanik","year":"2013","journal-title":"Clin Infect Dis"},{"key":"B12-20230819","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/QAD.0b013e32835cba6c","article-title":"Risk of Kaposi sarcoma during the first months on combination antiretroviral therapy.","volume":"27","author":"Lacombe","year":"2013","journal-title":"AIDS"},{"key":"B13-20230819","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/00126334-200108150-00003","article-title":"Evolution of cervical abnormalities among women with HIV-1: evidence from surveillance cytology in the women\u2019s interagency HIV study.","volume":"27","author":"Massad","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"B14-20230819","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1086\/344057","article-title":"Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus.","volume":"35","author":"Chin-Hong","year":"2002","journal-title":"Clin Infect Dis"},{"key":"B15-20230819","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(08)70103-7","article-title":"Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study.","volume":"9","author":"McCredie","year":"2008","journal-title":"Lancet Oncol"},{"key":"B16-20230819","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/aje\/kwt153","article-title":"Risk factors for anal cancer in persons infected with HIV: a nested case-control study in the Swiss HIV Cohort Study.","volume":"178","author":"Bertisch","year":"2013","journal-title":"Am J Epidemiol"},{"key":"B17-20230819","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/QAI.0b013e3181eef4f7","article-title":"Pulmonary infections and risk of lung cancer among persons with AIDS.","volume":"55","author":"Shebl","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"B18-20230819","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1093\/jnci\/djt309","article-title":"Circulating inflammation markers and prospective risk for lung cancer.","volume":"105","author":"Shiels","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"B19-20230819","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/1523-1747.ep12365586","article-title":"Excess of nevi related to immunodeficiency: a study in HIV-infected patients and renal transplant recipients.","volume":"107","author":"Grob","year":"1996","journal-title":"J Invest Dermatol"},{"key":"B20-20230819","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"key":"B21-20230819","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/dju382","article-title":"Risk of merkel cell carcinoma after solid organ transplantation.","volume":"107","author":"Clarke","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"B22-20230819","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.2215\/CJN.02020309","article-title":"Renal cystic diseases and renal neoplasms: a mini-review.","volume":"4","author":"Bonsib","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"B23-20230819","first-page":"77","article-title":"Development of adenocarcinoma and acquired cystic disease of the kidney in hemodialysis patients.","volume":"18","author":"Ishikawa","year":"1987","journal-title":"Princess Takamatsu Symp"},{"key":"B24-20230819","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1097\/00007890-199812270-00017","article-title":"Prospective pretransplant ultrasound screening in 206 patients for acquired renal cysts and renal cell carcinoma.","volume":"66","author":"Gulanikar","year":"1998","journal-title":"Transplantation"},{"key":"B25-20230819","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000013314","article-title":"Cancer in end-stage renal disease: potential factors involved -editorial-.","volume":"18","author":"Vamvakas","year":"1998","journal-title":"Am J Nephrol"},{"key":"B26-20230819","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0140-6736(07)61050-2","article-title":"Incidence of cancers in people with HIV\/AIDS compared with immunosuppressed transplant recipients: a meta-analysis.","volume":"370","author":"Grulich","year":"2007","journal-title":"Lancet"},{"key":"B27-20230819","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1471-2369-13-65","article-title":"Cancer risk among elderly persons with end-stage renal disease: a population-based case-control study.","volume":"13","author":"Shebl","year":"2012","journal-title":"BMC Nephrol"},{"key":"B28-20230819","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1053\/j.ajkd.2014.12.013","article-title":"Cancer incidence among US Medicare ESRD patients receiving hemodialysis, 1996-2009.","volume":"65","author":"Butler","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"B29-20230819","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrneph.2013.44","article-title":"Immune cell dysfunction and inflammation in end-stage renal disease.","volume":"9","author":"Betjes","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"B30-20230819","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1470-2045(09)70096-8","article-title":"A review of human carcinogens--Part B: biological agents.","volume":"10","author":"Bouvard","year":"2009","journal-title":"Lancet Oncol"},{"key":"B31-20230819","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1080\/01621459.1996.10476953","article-title":"A simple multivariate test for one-sided alternatives.","volume":"91","author":"Follmann","year":"1996","journal-title":"J Am Stat Assoc"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001751-201605000-00028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:27:16Z","timestamp":1786130836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001751-201605000-00028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,12]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2015040373","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,12]]}}}